These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33300153)

  • 1. Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.
    Kong D; Fan S; Sun L; Chen X; Zhao Y; Zhao L; Guo Z; Li Y
    Hematol Oncol; 2021 Apr; 39(2):222-230. PubMed ID: 33300153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.
    Kong D; Zhao L; Sun L; Fan S; Li H; Zhao Y; Guo Z; Lin L; Cui L; Wang K; Chen W; Zhang Y; Zhou J; Li Y
    J Cell Mol Med; 2018 Jul; 22(7):3627-3637. PubMed ID: 29673070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
    J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
    Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
    Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.
    Bi Y; Jiang Y; Li X; Hou G; Li K
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):499-505. PubMed ID: 33225417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
    Zhao L; Lv C; Sun L; Li Q; Wang Y; Wu M; Wang Y; Guo Z; Bian S; Kong D; Lin L; Wang Y; Zhou J; Li Y
    Invest New Drugs; 2021 Aug; 39(4):961-970. PubMed ID: 33566253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
    Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
    Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.
    Zhou J; Toh SH; Chan ZL; Quah JY; Chooi JY; Tan TZ; Chong PSY; Zeng Q; Chng WJ
    J Hematol Oncol; 2018 Mar; 11(1):36. PubMed ID: 29514683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J; Xue L; Hao H; Han Y; Yang J; Luo J
    Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M; Moharram SA; Marhäll A; Kazi JU
    Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
    Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
    Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of the Wnt/GSK3β/β‑catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer's disease model.
    Chen J; Long Z; Li Y; Luo M; Luo S; He G
    Int J Mol Med; 2019 Jul; 44(1):313-323. PubMed ID: 31115485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
    Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
    Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the role of MYCN in retinoblastoma by inhibiting p53 and activating wnt/βcatenin/Fra-1 signaling pathway by reducing DKK3.
    Chen X; Ouyang L; Ke N; Pi L; Zhou X
    Drug Dev Res; 2024 Aug; 85(5):e22222. PubMed ID: 39003564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
    Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
    Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
    Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
    Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt signalling is a bi-directional vulnerability of cancer cells.
    Duffy DJ; Krstic A; Schwarzl T; Halasz M; Iljin K; Fey D; Haley B; Whilde J; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2016 Sep; 7(37):60310-60331. PubMed ID: 27531891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
    Sun MM; Zhang MZ; Chen Y; Li SL; Zhang W; Ya GW; Chen KS
    J Int Med Res; 2012; 40(5):1636-43. PubMed ID: 23206445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.